-
PharmaEssentia’s Besremi Receives Approval for Polycythemia Vera Treatment in China
•
PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1), a biopharmaceutical company based in Taiwan, has announced that its drug Besremi (ropeginterferon alfa-2b) has been approved by the National Medical Products Administration (NMPA) to treat adult polycythemia vera (PV) in China. This ultra-long-acting interferon, developed in-house, is already registered in the European Union,…
-
PharmaEssentia Announces Licensing Agreement with WuXi Biologics for Antibody Development
•
Taiwan-based PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1) has entered into a licensing agreement with China’s WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO). This agreement grants PharmaEssentia exclusive rights for research and development, manufacturing, and marketing of specific antibody sequences targeting the myeloid immune checkpoint,…
-
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
•
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of Global Depositary Receipt (GDR) shares. A total of 34 million shares of common stock were offered at a price of USD 13.61 per share, resulting in a capital raise of USD 462.7 million. The shares…
